US stock futures dip as Nvidia earnings spark little cheer
ALPHARETTA, GA - Avanos Medical (TASE:BLWV), Inc. (NYSE:AVNS), a leading producer of medical devices and supplies with a market capitalization of $567 million, announced the results of its 2025 Annual Meeting of Stockholders today. The company’s stock, currently trading near its 52-week low of $11.84, has seen a challenging year with a 30% decline over the past 12 months. According to InvestingPro analysis, the stock appears undervalued at current levels. Held at the company’s headquarters on April 24, 2025, the meeting saw the approval of all proposed items on the agenda, including the election of board members and the ratification of the company’s independent auditor.
Stockholders voted to elect five directors to one-year terms, with Gary D. Blackford, Dr. Lisa Egbuonu-Davis, Indrani L. Franchini, Patrick J. O’Leary, and Dr. Julie Shimer securing their positions on the board. The election results showed a strong majority in favor, with over 36 million votes for each nominee and approximately 2.67 million broker non-votes.
In addition, the appointment of Deloitte & Touche LLP as the independent auditors for the fiscal year 2025 was ratified with over 40 million votes for the proposal, indicating stockholder confidence in the firm’s role.
The compensation of the company’s named executive officers (NEOs) also received approval from the majority of the shareholders, with more than 35 million votes in favor, signifying support for the company’s executive pay structure.
A significant amendment to the company’s 2021 Long Term Incentive Plan was passed, allowing for an increase of 2,250,000 shares reserved for issuance under the plan. This proposal garnered over 27 million votes for approval, reflecting stockholder endorsement for the company’s incentive strategies.
Overall, the meeting outcomes demonstrated strong shareholder engagement, with approximately 93.64% of the outstanding shares represented in person or by proxy. Avanos Medical’s commitment to transparency and stockholder communication was evident in the smooth proceedings and decisive voting results. The company maintains a healthy financial position with a current ratio of 2.37, indicating strong liquidity. InvestingPro data reveals that while the company faced profitability challenges in the past year, analysts expect a return to profitability in 2025 with projected earnings of $1.16 per share. For deeper insights into Avanos Medical’s financial health and growth prospects, investors can access the comprehensive Pro Research Report, available exclusively on InvestingPro along with 8 additional key insights about the company.
The information presented in this article is based on a press release statement.
In other recent news, Avanos Medical reported financial results for the fourth quarter of 2024, surpassing earnings and revenue expectations. The company achieved an earnings per share (EPS) of $0.43, exceeding the anticipated $0.40, and revenue reached $179.6 million, above the forecasted $177.23 million. Avanos also completed the sale of its Respiratory Health business, which aligns with its strategic focus on restructuring and cost transformation. In executive developments, Avanos appointed David Pacitti as the new CEO, effective April 14, 2025, following Michael C. Greiner’s departure from the interim CEO role. Greiner’s exit entitles him to a severance package, including a $2.1 million payment and other benefits. Avanos has also appointed Jason M. Pickett as the new Interim Chief Financial Officer. Analyst firm Stifel maintained a Hold rating on Avanos Medical’s stock, citing the need for the company to demonstrate consistent operational performance under its new leadership. These developments reflect Avanos’s ongoing efforts to adapt its leadership and strategic direction in the evolving healthcare industry.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.